Novo Nordisk expands Ozempic's turf with new FDA nod to curb kidney disease risks
When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical director suggested the results could help set a new standard for “holis | The FDA on Tuesday gave Ozempic a thumbs-up to reduce the risk of kidney disease worsening,
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
11d
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback